BD announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the market for biologic therapies.
The BD Neopak Glass Prefillable Syringe platform is designed to address development needs for biologic drugs and its customers have received approval to use this platform for more than 24 indications, including Crohn's disease, atopic dermatitis, cardiovascular disease and various rare diseases.
BD has expanded usability of this platform with the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today's limits versus a standard half-inch needle.
In addition to the usability enhancements, our manufacturing site in Le Pont-de-Claix, France has successfully integrated a high-volume manufacturing line for the BD Neopak Glass Prefillable Syringe platform, increasing the production capacity of a single line by sevenfold. This achievement marks a significant milestone for BD, enabling unprecedented large-scale production of advanced BD glass syringes.
The launch of our BD Neopak XtraFlow Glass Prefillable Syringe allows developers to take advantage of a single platform approach while dismantling existing design barriers such as drug viscosity. The addition of the high-volume line at the Pont-de-Claix site allows BD to be more resilient to supply constraints.
